Verge Genomics

What is Verge Genomics?

Verge Genomics specializes in accelerating drug discovery for complex neurodegenerative diseases by leveraging extensive human genomic data and advanced computational biology. Their proprietary CONVERGE® platform integrates multi-omic patient data with machine learning to identify and validate therapeutic targets directly from human brain tissue, improving the likelihood of clinical success. The company focuses on diseases such as ALS and Parkinson’s, advancing programs from discovery through clinical development while collaborating with partners like Eli Lilly.

Key Features

• All-in-Human Data Platform

  Utilizes large-scale human brain tissue datasets and patient genomics to identify disease-relevant gene networks and targets, bypassing limitations of animal models.

• CONVERGE® Machine Learning System

  A closed-loop platform combining multi-omic data with computational tools to predict drug targets with higher clinical translatability.

• Integrated Target Validation

  Combines computational predictions with experimental validation using patient-derived cells and advanced biological assays to establish causality and therapeutic potential.

• Focus on Neurodegenerative Diseases

  Dedicated to developing treatments for challenging conditions like ALS, Parkinson’s disease, and frontotemporal dementia with high unmet medical needs.

• Collaborative Drug Development

  Engages in strategic partnerships to advance promising targets into clinical trials, exemplified by a multi-year collaboration with Eli Lilly.

Use Cases

• Target Discovery for Neurodegeneration : Identifying novel gene targets and pathways involved in diseases such as ALS and Parkinson’s directly from patient data.
• Drug Candidate Development : Designing and optimizing therapeutic compounds based on validated targets to restore healthy gene network function.
• Clinical Biomarker Identification : Linking gene expression and patient clinical data to find biomarkers that track disease progression and treatment response.
• Accelerating Translational Research : Using human-centric data and machine learning to improve prediction of clinical outcomes and reduce drug development failures.

FAQs